Tigecycline Dosing Regimen
For adults with severe infections, administer tigecycline as a 100 mg IV loading dose followed by 50 mg IV every 12 hours, infused over 30-60 minutes 1.
Standard Adult Dosing
- Loading dose: 100 mg IV
- Maintenance dose: 50 mg IV every 12 hours
- Infusion time: 30-60 minutes
- Treatment duration:
High-Dose Regimen for Severe Infections
For critically ill patients with multidrug-resistant infections, particularly carbapenem-resistant Enterobacterales (CRE) causing complicated intra-abdominal infections or vancomycin-resistant enterococci (VRE), consider high-dose tigecycline: 100 mg IV loading dose followed by 100 mg IV every 12 hours 3. This higher maintenance dose has been used successfully in severe infections when standard dosing may be inadequate, though it carries increased risk of adverse effects 3.
Hepatic Impairment Adjustments
- Mild to moderate impairment (Child-Pugh A or B): No dose adjustment required 1
- Severe impairment (Child-Pugh C): 100 mg loading dose, then reduce maintenance to 25 mg IV every 12 hours 1
- Monitor these patients closely for treatment response and hepatotoxicity
Renal Impairment
No dose adjustment is necessary for any degree of renal impairment, including patients on hemodialysis or continuous renal replacement therapy 1. Tigecycline is not significantly removed by dialysis.
Critical Clinical Considerations
When to Use Standard vs. High-Dose
The evidence strongly supports reserving tigecycline for specific clinical scenarios:
- Standard dose (50 mg q12h): Appropriate for approved indications (cSSSI, cIAI) with susceptible organisms where MIC ≤1 mg/L 3
- High dose (100 mg q12h): Consider for severe infections with higher MIC values or when treating CRE/VRE in critically ill patients 3
Important Limitations and Warnings
Do NOT use tigecycline monotherapy for:
- CRAB (carbapenem-resistant Acinetobacter baumannii) pneumonia 2
- Hospital-acquired or ventilator-associated pneumonia 1
- Bloodstream infections (poor outcomes documented) 3
- Diabetic foot infections 1
Tigecycline carries a black box warning for increased all-cause mortality (0.6% absolute risk increase) compared to comparators 1. Reserve it for situations when alternative treatments are not suitable.
Combination Therapy Recommendations
For CRE complicated intra-abdominal infections, tigecycline can be combined with:
However, newer agents like ceftazidime-avibactam, meropenem-vaborbactam, or imipenem-relebactam are preferred over tigecycline for CRE when available 2, 4.
Monitoring Parameters
Given recent evidence of dose-dependent hepatotoxicity:
- Baseline and serial liver function tests are essential 5, 6, 7
- Hepatotoxicity incidence: 23-35% in critically ill patients 6, 7
- Median time to liver injury: 4 days 7
- Risk increases with cumulative dose and treatment duration 6, 7
- Consider therapeutic drug monitoring if available: target Cmin <0.535 mg/L and C6h <0.690 mg/L to reduce hepatotoxicity risk 6
Monitor closely for nausea (28.5%), vomiting (19.4%), and diarrhea (11.6%)—the most common adverse effects 1, 8.
Pediatric Considerations
Avoid tigecycline in pediatric patients unless no alternative exists due to increased mortality risk in adults and tooth development concerns in children <8 years 1. If absolutely necessary:
- Ages 8-11 years: 1.2 mg/kg IV q12h (maximum 50 mg per dose)
- Ages 12-17 years: 50 mg IV q12h
- Not recommended for children <8 years 1